With type 2 diabetes, the same dose takes off about a third less
STEP 2 gave 1,210 adults with obesity and type 2 diabetes 2.4 mg weekly for 68 weeks and weight fell 9.6%, against 14.9% in the sibling trial without diabetes.
What the study found
On the same dose, weight falls 9.6% with diabetes and 14.9% without
Which trial a number came from decides what it means. STEP 2 gave 1,210 adults with obesity and type 2 diabetes the same 2.4mg weekly dose for the same 68 weeks, and weight fell 9.6% against 3.4% on placebo. Roughly a third smaller than the sibling trial in people without diabetes.
The caveat · Background diabetes drugs varied
Both trials were funded by Novo Nordisk. Participants stayed on varying background diabetes medication, which is part of what separates the two groups rather than diabetes on its own. Gastrointestinal side effects reached 63.5% here against 34.3% on placebo.